Metformin blocks MYC protein synthesis in colorectal cancer via mTOR-4EBP-eIF4E and MNK1-eIF4G-eIF4E signaling
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Molecular Oncology, 12, 11, S. 1856-1870
- Ereignis
-
Veröffentlichung
- (wo)
-
Augsburg
- (wer)
-
Universität Augsburg
- (wann)
-
2018
- Ereignis
-
Veröffentlichung
- (wer)
-
Wiley
- (wann)
-
2018
- Urheber
- DOI
-
10.1002/1878-0261.12384
- URN
-
urn:nbn:de:bvb:384-opus4-1023284
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:42 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Shen, Peng
- Reineke, Lucas C.
- Knutsen, Erik
- Chen, Meng
- Pichler, Martin
- Ling, Hui
- Calin, George A.
- Universität Augsburg
- Wiley
Entstanden
- 2018
Ähnliche Objekte (12)
So finden Sie den passenden Coach : der Wegweiser zum Erfolg - Antworten, die das Internet nicht gibt
MicroRNAs: clinical relevance in colorectal cancer
Best of ASCO 2022: bladder cancer
The role of Skp2 and its substrate CDKN1B (p27) in colorectal cancer
To Wnt or lose: the missing non-coding linc in colorectal cancer
Current status of long non-coding RNAs in human cancer with specific focus on colorectal cancer
MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer
Prediction of response in melanoma therapy by systemic inflammatory response – one size fits not all
Non-smoking-associated lung cancer: a distinct entity in terms of tumor biology, patient characteristics and impact of hereditary cancer predisposition
Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-magnitude of clinical benefit scale (ESMO-MCBS) version 1.1
MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients
Epidermal growth factor receptor inhibitors in adjuvant treatment of lung cancer — the more specific, the better?
So finden Sie den passenden Coach : der Wegweiser zum Erfolg - Antworten, die das Internet nicht gibt
MicroRNAs: clinical relevance in colorectal cancer
Best of ASCO 2022: bladder cancer
The role of Skp2 and its substrate CDKN1B (p27) in colorectal cancer
To Wnt or lose: the missing non-coding linc in colorectal cancer
Current status of long non-coding RNAs in human cancer with specific focus on colorectal cancer
MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer
Prediction of response in melanoma therapy by systemic inflammatory response – one size fits not all
Non-smoking-associated lung cancer: a distinct entity in terms of tumor biology, patient characteristics and impact of hereditary cancer predisposition
Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-magnitude of clinical benefit scale (ESMO-MCBS) version 1.1
MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients
Epidermal growth factor receptor inhibitors in adjuvant treatment of lung cancer — the more specific, the better?
So finden Sie den passenden Coach : der Wegweiser zum Erfolg - Antworten, die das Internet nicht gibt
MicroRNAs: clinical relevance in colorectal cancer
Best of ASCO 2022: bladder cancer
The role of Skp2 and its substrate CDKN1B (p27) in colorectal cancer
To Wnt or lose: the missing non-coding linc in colorectal cancer
Current status of long non-coding RNAs in human cancer with specific focus on colorectal cancer
MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer
Prediction of response in melanoma therapy by systemic inflammatory response – one size fits not all
Non-smoking-associated lung cancer: a distinct entity in terms of tumor biology, patient characteristics and impact of hereditary cancer predisposition
Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-magnitude of clinical benefit scale (ESMO-MCBS) version 1.1
MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients